March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ImmunityBio, Inc. (NASDAQ: IBRX). The investigation focuses on ImmunityBio executive officers and ...
By Siddhi Mahatole March 24 (Reuters) - Shares of ImmunityBio fell 26% on Tuesday after the U.S. Food and Drug Administration ...
Shares of ImmunityBio plummeted Tuesday after the Food and Drug Administration said the biotech company used false or ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best NASDAQ stocks under $30 to buy. On March 17, ImmunityBio announced that the ...
CEO Richard Adcock used a presentation at the Citizens Life Sciences Conference to outline the company’s commercial progress ...
Is IBRX a good stock to buy now? We came across a bullish thesis on ImmunityBio, Inc. on r/pennystocks by Bailey-96. In this article, we will summarize the bulls’ thesis on IBRX. ImmunityBio, Inc.’s ...
Through its Cancer BioShield platform and Anktiva biologic product, ImmunityBio stimulates natural killer cells, cytotoxic T cells, and memory T cells, helping patients fight a growing number of ...
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...
Hosted on MSN
Why ImmunityBio stock is soaring again today
ImmunityBio's sales grew 700% in 2025, with fourth-quarter revenue rising 20% quarter over quarter. These excellent results extend an incredible run of good news for the up-and-coming biotech stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results